Target achievement and cardiovascular event rates with Lomitapide in homozygous Familial Hypercholesterolaemia

BACKGROUND: Homozygous familial hypercholesterolaemia (HoFH) is characterized by a markedly increased risk of premature cardiovascular (CV) events and cardiac death. Lomitapide reduces low-density lipoprotein cholesterol (LDL-C) levels; however, the probable impact on LDL-C goals and CV events is un...

Descripción completa

Detalles Bibliográficos
Autores principales: Blom, Dirk J., Cuchel, Marina, Ager, Miranda, Phillips, Helen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6011273/
https://www.ncbi.nlm.nih.gov/pubmed/29925433
http://dx.doi.org/10.1186/s13023-018-0841-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6011273/
https://www.ncbi.nlm.nih.gov/pubmed/29925433
http://dx.doi.org/10.1186/s13023-018-0841-3

Ejemplares similares